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Increasing empirical evidence suggests that many genetic variants influence multiple distinct phenotypes. When cross-phenotype ef-
fects exist, multivariate association methods that consider pleiotropy are often more powerful than univariate methods that model
each phenotype separately. Although several statistical approaches exist for testing cross-phenotype effects for common variants,
there is a lack of similar tests for gene-based analysis of rare variants. In order to fill this important gap, we introduce a statistical
method for cross-phenotype analysis of rare variants using a nonparametric distance-covariance approach that compares similarity in
multivariate phenotypes to similarity in rare-variant genotypes across a gene. The approach can accommodate both binary and contin-
uous phenotypes and further can adjust for covariates. Our approach yields a closed-form test whose significance can be evaluated
analytically, thereby improving computational efficiency and permitting application on a genome-wide scale. We use simulated data
to demonstrate that our method, which we refer to as the Gene Association withMultiple Traits (GAMuT) test, provides increased power
over competing approaches. We also illustrate our approach using exome-chip data from the Genetic Epidemiology Network of
Arteriopathy.Introduction
The 1980s were an era of debate in the theoretical quanti-
tative genetics community between two competing
schools of thought.1 The question of interest was ‘‘What
is the nature of genetic variation contributing to complex
traits?’’ On one hand there was the infinitesimal school,2
which argued that complex traits were the result of muta-
tion/selection balance under stabilizing selection. The var-
iants that contributed to traits were a combination of very
rare alleles of potentially large effect combined with many
common alleles of exceedingly small effect. The opposing
camp, sometimes called Neo-Darwinian,3 argued that a
substantial fraction of genetic variation was contributed
by high-frequency alleles of large effect, whose frequency
was maintained through balancing selection.4 The neo-
Darwinian’s school leveled two interrelated and poten-
tially fatal criticisms at the infinitesimal camp: believing
in the infinitesimal model requires one to simultaneously
accept that (1) much of the standing genetic variation is
due to extremely rare alleles of large effect and (2) a large
fraction of the genome of an organism is contributing to
nearly every phenotype.3 That means that nearly every
rare, large-effect allele must simultaneously be contrib-
uting to a large number of different traits. The neo-
Darwinian school argued that the only alternative to
believing in this worldview was to suppose that a substan-
tial fraction of the variation in complex traits was contrib-
uted to by common alleles of large effect.
Perhaps without explicitly acknowledging it,5–7 the
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The Amementally testing the predictions of the neo-Darwinian
school. We now know that, by and large, common alleles
of large effect do not exist. When considered collectively,
common variants can explain a sizable proportion of the
heritability for many complex traits like height, body-
mass index, and cardiovascular disease.8–10 However, com-
mon trait-influencing variants identified and replicated by
GWASs tend to have very modest effect sizes. Much of the
genetic contributors to complex traits still remain undis-
covered and are presumably due to very rare variation.
Thus, although it might be time to reject the neo-
Darwinian worldview in favor of the infinitesimal model,
we can not logically do so without simultaneously
embracing the central Neo-Darwinian critique of the infin-
itesimal school: most traits should be affected by a large
fraction of the genome, and rare alleles of large effect
should be generally highly pleiotropic for seemingly unre-
lated phenotypes. Moreover, if we adopt this worldview
whole-heartedly, it suggests a paradigm shift in how we
should approach genetic association studies.
If rare alleles of large effect are both ubiquitous and
generally highly pleiotropic, we can leverage this to
discover genes involved in complex traits. When pleiot-
ropy exists, an analysis that models multiple phenotypes
simultaneously in a multivariate or ‘‘cross-phenotype’’
framework will provide greater statistical power than a
standard univariate method that considers each pheno-
type separately.11,12 Because underlying genetic pleiotropy
will induce phenotypic correlation, a genetic association
that exists with multiple traits will be more readily detect-
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information provided by cross-phenotype correlation. This
information is ignored in univariate analyses. Addition-
ally, when pleiotropy is suspected, allowing for cross-
phenotype associations might yield a more biologically
plausible statistical model and potentially help to explain
shared pathogenesis.11,13
Cross-phenotype association tests for common variants
using SNPs have demonstrated considerable success.14,15
For example, common-variant cross-phenotype associa-
tion has been reported among Crohn disease and ulcera-
tive colitis,16 different facial morphology measures,17
and among bipolar disorder, autism spectrum disorder,
ADHD, major depressive disorder, and schizophrenia.18
However, although there are several excellent statistical
methods appropriate for cross-phenotype analysis of com-
mon genetic variants,19–24 theory tells us that rare alleles
cannot be ignored and that pleiotropy due to rare alleles
should be more pronounced. Unfortunately, there is a
shortage of analogous statistical approaches to assess
cross-phenotype associations of rare genetic variants.
Currently, most cross-phenotype association methods
are designed to assess the effect of a single polymorphism
at a time; however, in rare variant analysis, a test typically
requires aggregation of information frommultiple rare var-
iants within a gene simultaneously. One possible rare-
variant cross-phenotype test is a modification of the
common-variant method of Maity et al.23 Although the
Maity approach was developed to study the relationship
between multiple SNPs in a gene and multiple correlated
phenotypes using mixed models, it could be adapted to
consider rare variants rather than common SNPs. Addi-
tionally, Wang et al. proposed an alternative gene-level
test of pleiotropy that uses multivariate functional linear
models (MFLM).25 However, we note that the approaches
of Maity and Wang allow only for continuous phenotypes
and thus cannot be applied to important categorical phe-
notypes like presence or absence of a disease. Ideally, a
cross-phenotype test of rare variation should be able to
handle both continuous and categorical phenotypes and
be able to scale efficiently to handle an arbitrary number
of phenotypes. Here, we present a method that meets
both these criteria.
We propose a method called Gene Association with Mul-
tiple Traits (GAMuT) for association testing of high-dimen-
sional phenotype data with high-dimensional genotype
data. GAMuT relies on a machine-learning framework
called kernel distance-covariance (KDC)26–30 to provide a
nonparametric test of independence between a set of phe-
notypes and a set of genetic variants. The KDC framework
used by GAMuTassesses whether pairwise phenotypic sim-
ilarity in a sample is independent of pairwise rare-variant
genotypic similarity in a gene or region of interest. The
framework allows for an arbitrary number of phenotypes
that can be both continuous and/or categorical in nature
and similarly allows for an arbitrary number of genotypes,
thereby permitting gene-based testing of rare variants.
GAMuT can correct for important covariates, such as mea-526 The American Journal of Human Genetics 98, 525–540, March 3sures of ancestry to account for population stratification.
Furthermore, GAMuT is a closed form test that yields ana-
lytic p values, thus scaling easily to genome-wide analysis.
Thismanuscript is organized as follows. First, we develop
GAMuT using the KDC framework and show how we
derive analytic p values for this test. We also describe
how we can adjust for covariates in GAMuT. Additionally,
we describe an efficient resampling strategy that can be
used if one wishes to construct a GAMuT test multiple
times using different similarity measures for phenotypes
and/or genotypes. This resampling strategy appropriately
corrects for multiple testing but is far less computationally
intensive than standard permutations. Next, we present
simulation work comparing GAMuT to MFLM and univar-
iate SKAT31 analysis of rare variants under various trait-
influencing models and demonstrate that our analytic
strategy can be considerably more powerful than these
competing approaches, both when pleiotropy truly exists
and also when variants influence only one of the pheno-
types under consideration. Finally, we apply GAMuT to
perform exome-chip analysis of multivariate phenotypic
measures of cardiovascular health using data from the Ge-
netic Epidemiology Network of Arteriopathy (GENOA).32Material and Methods
Assumptions and Notation
Weassumea sampleofN subjectswhohavebeenmeasured formul-
tiple phenotypes of interest and possess sequencing or exome-
chip data in a target gene or region. For subject j (j ¼ 1,.,N), we
define Pj ¼ (Pj,1, Pj,2, ., Pj,L) as the L phenotypes of the subject
and allow such phenotypes to be continuous and/or categorical
in nature. We then define a matrix of phenotypes for the entire
sample P ¼ ðPT1 ;PT2 ;.;PTNÞT , which is of dimension N 3 L. Simi-
larly, we defineGj ¼ (Gj,1, Gj,2,., Gj,V) to be the genotypes of sub-
ject j atV rare-variant sites in the geneof interest,whereGj,v is coded
as the number of copies of the minor allele that the subject pos-
sesses at variant v. We then construct the matrix of rare-variant
genotypes for the sample as G ¼ ðGT1 ;GT2 ;.;GTNÞT which is of
dimension N 3 V.
GAMuT Test of Cross-Phenotype Associations
We create GAMuT to examine the relationship between pheno-
types P and rare-variant genotypes G. GAMuT is based on a
KDC machine-learning technique,26–30 which allows nonpara-
metric tests of independence between two distinct sets of multi-
variate variables. For each set of multivariate variables, KDC
constructs anN3Nmatrix with individual elements of thematrix
corresponding to similarity (or dissimilarity) in the variables
among different pairs of subjects. KDC then evaluates whether
the pairwise elements in the similarity matrix of one set of multi-
variate variables is independent of the pairwise elements in the
similarity matrix for the other set of multivariate variables.
Leveraging the KDC framework, we create a rare-variant test of
pleiotropy to test for independence between P (N 3 L matrix of
multivariate phenotypes) and G (N 3 V matrix of multivariate
rare-variant genotypes). To do this, we first develop an N 3 N
phenotypic-similarity matrix Y (based on P) and an N 3 N geno-
typic-similarity matrix X (based on G). The choice of how to, 2016
model pairwise similarity or dissimilarity for a set of multivariate
outcomes is quite flexible. For example, for phenotypes P, we
can model the matrix Y using a projection matrix,33,34 such that
Y ¼ P(PTP)1PT. We can also construct the model Y using user-
selected kernel functions.31,35–37 Denote the kernel function
y(Pi, Pj) as the measure of similarity between subjects i and j
across the L phenotypes. We can model y(Pi, Pj) using kernel
similarity functions like the linear kernel, yðPi;PjÞ ¼
PL
l¼1Pi;lPj;l;
a quadratic kernel, yðPi;PjÞ ¼ ð1þ
PL
l¼1Pi;lPj;lÞ2; or a Gaussian
kernel, yðPi;PjÞ ¼ expð
PL
l¼1ðPi;lPj;lÞ2=dÞ, where d is a tuning
parameter.
For genotypes G, we model the corresponding matrix X using
kernel functions x(Gi, Gj) that can take the same form (e.g., linear,
quadratic, or Gaussian) used to construct y(Pi, Pj). A few genetic-
specific kernel functions also exist, like the identity-by-state (IBS)
kernel, xðGi;GjÞ ¼
PV
v¼1IBSðGi;vGj;vÞ=2V, where IBS(Gi,v Gj,v)
denotes the number of alleles (0, 1, or 2) shared IBS by subjects i
and j at variant v. Also, we might wish to further augment
x(Gi, Gj) to preferentially upweight the contributions of particular
rare variants in G over others in the gene. For example, we may
wish to give more weight to variants that are more rare in the pop-
ulation or to variants that are predicted to be deleterious in na-
ture.38–40 We can do this by creating a diagonal weight matrix
W ¼ diag(w1, w2, ., wV), where wv reflects the relative weight
for the vth variant in the gene. Using W, we can then create a
weighted linear kernel function asX¼GWGT. Derivation of other
weighted kernel functions is straightforward.
Once we construct the similarity matrixes Y and X, we derive
our GAMuT approach as a test of independence between the
elements of these two matrices. We first center each matrix as
Yc ¼ HYH and Xc ¼ HXH. Here,H ¼ ðI  1N1TN=NÞ is a centering
matrix with propertyHH¼H, I is an identitymatrix of dimension
N, and 1N is an N 3 1 vector with each element equal to 1. Using
Yc and Xc, we construct our GAMuT test of independence of the
two matrices as
TGAMuT ¼ 1
N
traceðY cXcÞ: (Equation 1)
Under the null hypothesis where the two matrices are indepen-
dent, TGAMuT follows the same asymptotic distribution as
1
N2
X
i;j
lX;ilY;iz
2
ij; (Equation 2)
where lX,i is the i
th ordered non-zero eigenvalue ofXc, lY,j is the j
th
ordered non-zero eigenvalue of Yc, and z
2
ij are independent and
identically distributed c21 variables.
30 Given L phenotypes and V
rare-variant sites, and further assuming sample size N is larger
than both L and V, the maximum number of possible elements
in the summation will be L*V.
Based on the KDC literature, we could derive the p value of the
GAMuT test approximately using a gamma distribution26 or
instead via permutation techniques.28,30 In our experience, the
gamma approximation is accurate for p values as small as 0.01
but becomes less accurate in themore extreme tails of the distribu-
tion (results not shown). Given that large-scale genetic studies
require p values much smaller than 0.01 to declare significance
in the presence of multiple testing, the gamma approximation is
not suitable in this setting. The derivation of p values using per-
mutations is a valid alternative, but computationally demanding
and difficult to scale to genome-wide analyses. Consequently,
we instead derive p values for GAMuT using Davies’ exact
method,41 which is a computationally efficient method to provideThe Ameaccurate p values in the extreme tails of tests that follow mixtures
of chi-square variables.31 An implementation of Davies’ method is
available in the R package CompQuadForm.42Relationship of GAMuT to Other Multivariate
Association Tests
Although the form of the GAMuT test is quite general, we note
that specific choices of Y and X can lead to test statistics that
have similar forms to other multivariate association tests previ-
ously published in the literature. If we assume a projection matrix
Y for the phenotypes (with each phenotype mean centered prior
to analysis) and assume X is the Gower distance (or some other
measure of genetic dissimilarity as opposed to similarity), the
GAMuT test has a form similar to the numerator of existing multi-
variate distance matrix regression (MDMR) tests.33,34,43 We note,
however, that MDMR procedures typically require permutations
for inference whereas we can derive analytic p values of GAMuT
directly via Davies’ method. MDMR tests’ reliance on permuta-
tions limits application of these techniques to smaller-scale studies
such as candidate-gene investigations. On the other hand,
GAMuT’s efficient derivation of analytic p values enables the
approach to be applied efficiently to whole-exome and whole-
genome sequencing projects.
In addition to MDMR, we also note that applying GAMuTusing
a linear kernel to model the phenotype similarity matrix Y and to
further model the genotype similarity matrix X results in a test
that becomes a rare-variant version of the multivariate kernel-ma-
chine test of Maity et al.23,27 created for the analysis of common
variants. The approach of Maity, however, required perturbations
to calculate p values of individual tests where again GAMuT can
derive p values analytically via Davies’ method.GAMuT Testing Assuming Multiple Candidate
Matrices
The GAMuT test in the previous section requires a priori selection
of the functions used to construct the phenotypic similarity ma-
trix Y and genotypic similarity matrix X. In practice, though, it
is often unclear what the optimal choices for Y and X should be.
For example, an investigator might want to model phenotypes P
in the matrix Y using both the projection matrix and the linear
kernel function. Also, an investigator might want to construct
the genotype-similarity matrix X under different kernel functions
(e.g., linear and IBS) and assuming different weight functions (e.g.,
minor allele frequency [MAF] weights, functionality weights). If
we construct GAMuT tests under multiple different phenotypic
and genotypic similarity matrices, we then need to adjust for the
additional tests that were performed. To adjust for additional tests,
one could use a Bonferroni correction or apply permutations.
However, a Bonferroni correction probably will lead to conserva-
tive inference because these tests are correlated, whereas permuta-
tions are computationally demanding and unappealing on a
genome-wide level.
Rather than use Bonferroni or permutations, we follow the ideas
of Zhang et al.30 andWu et al.44 to develop a perturbation (resam-
pling) approach to correct for testing of multiple candidate
matrices in GAMuT that is more computationally efficient than
standard permutations. Assume we test M different combinations
ofYandX. For combinationm (m¼ 1,.,M), we let p(m) denote the
uncorrected GAMuT p value and further let l
ðmÞ
Y and l
ðmÞ
X denote
the vectors of all non-zero eigenvalues for Yc and Xc, respectively,
for that combination.rican Journal of Human Genetics 98, 525–540, March 3, 2016 527
We wish to determine whether the minimum observed p value
across the M tested combinations is significant after adjustment
for theM correlated tests. To do this, we use perturbations to create
an empirical distribution of minimum p values across the sameM
combinations under the null hypothesis of no association. We
then calculate our corrected p value by comparing our minimum
observed p value to the empirical minimum p values generated
under the null hypothesis induced by the perturbation process.
In particular, we implement the following:
(1) Calculate the minimum observed p value across the M
different combinations as p ¼ min1%m%MpðmÞ.
(2) For perturbation k (k ¼ 1,.K), generate a set of indepen-
dent c21 variables z*k of length equal to K*V.
(3) For each combination m, calculate the test T
ðmÞ
l ¼
1=N2
P
i;jl
ðmÞ
X;i l
ðmÞ
Y;j z

ij;k and obtain a new p value p
ðmÞ
k via
Davies’ method.
(4) Evaluate the minimum p value across all M combinations
for perturbation k as pk ¼ min1%m%MpðmÞk .
(5) Repeat steps 2–4 a total of K times and obtain the empirical
distribution of uncorrectedminimump values p1; p

2;.; p

K.
(6) Derive the final p value as p ¼ K1P I½pk%p0Adjusting for Covariates
Pleiotropic tests must adjust for important covariates, such as prin-
cipal components of ancestry, to avoid potential confounding of
results. We can control for confounders before applying GAMuT
by regressing each phenotype separately on covariates of interest
and then using the residuals to form the phenotypic similarity ma-
trix Y. Although residualizing binary phenotypes is not standard,
studies have suggested that this procedure does not affect the val-
idity of genetic association tests in case-control studies.45,46 As we
describe in the Results, the residualizing procedure provides an
effective correction for confounders in the analysis of binary out-
comes within our simulated datasets.Simulations
We conducted simulations to verify that GAMuT properly pre-
serves type I error and to assess power of GAMuT relative to
competing approaches for genetic analysis of multiple pheno-
types. To create genetic data for these simulations, we generated
20,000 haplotypes of 30 kb in size using COSI, a coalescent model
that mimics LD pattern, local recombination rate, and population
history for individuals of European descent.47 To create multivar-
iate phenotype data, we assume either six or ten phenotypes for
each subject generated from a multivariate normal distribution
with mean vector 0 and L 3 L residual correlation matrix S. To
model the residual correlation matrix, we considered scenarios
of low residual correlation among phenotypes (pairwise correla-
tion among phenotypes selected from a uniform (0, 0.3) distribu-
tion), moderate residual correlation (pairwise correlation selected
from a uniform (0.3, 0.5) distribution), and high residual correla-
tion (pairwise correlation selected from a uniform (0.5, 0.7)
distribution). To generate binary traits, we defined phenotype
measurements for the top quartile as affected (Pi,l ¼ 1) and defined
1st–3rd quartile measurements as controls (Pi,l ¼ 0). We considered
sample size N of either 1,000 or 2,500 subjects.
To investigate the performance of GAMuT under confounding
and to assess whether the approach can successfully adjust for rele-
vant covariates in this setting, we also simulated phenotypes un-528 The American Journal of Human Genetics 98, 525–540, March 3der a confounding model where phenotypes were independent
of genotypes, but both phenotypes and genotypes are associ-
ated with a normally distributed covariate Z. We simulated
phenotypes correlated with the covariate Z under the model
p  MVNð0:2Z;PÞ, where Z denotes the N 3 1 sample vector of
covariates. To simulate correlation between rare-variant genotypes
and covariate, we let 5% of the rare variants in our haplotypes be
causal. We set effect size, bZ,r, of each causal genetic variant r on Z,
as bZ;r ¼ ð0:3þ Nð0;0:1ÞÞ  jlog10ðMAFrÞ j , whereMAFr is the minor
allele frequency of causal variant r. Evaluating type I error under
this model allows us to verify that our approach to controlling
for confounders is valid.
We also performed type I error calculations to examine the val-
idity of our resampling approach to adjust for multiple similarity
matrices when applying GAMuT. For a given null dataset, we
applied GAMuTusing three combinations of phenotype similarity
matrices Y and genotype similarity matrices X:
(1) Model phenotypes using a projection matrix, model geno-
types using a weighted linear kernel.
(2) Model phenotypes using a linear kernel, model genotypes
using a weighted linear kernel.
(3) Model phenotypes using a projection matrix, model geno-
types using an unweighted linear kernel.
We then implement the perturbation procedure described
above to obtain a p value accounting for testing the three com-
binations of similarity matrices. For both continuous and
binary null simulations, we applied GAMuT to 10,000 simulated
datasets.
For power models, we considered simulation designs similar to
those proposed in the original SKAT paper.31 We simulated data-
sets in which 5% of the rare variants in our haplotypes were
modeled as causal. We set effect size of each causal variant, r, for
phenotype l, br,l, as br;l ¼ ð0:4þ Nð0;0:1ÞÞ  jlog10ðMAFrÞ j . This
formulation sets mean effect size of causal variant r as inversely
proportional to its MAF, such that very rare variants have on
average a larger effect size than less rare variants. The mean effect
size is based on the simulations performed for Wu et al.’s original
evaluation of SKAT.31 Allowing br,l to vary around a normal distri-
bution maintains the relationship between MAF and effect size
while allowing the variant to have a slightly different effect size
for each phenotype.
We performed power simulations both in situations where there
was no pleiotropy (i.e., only one of the modeled phenotypes was
associated with the rare causal variants) and also when there was
pleiotropy. Under pleiotropy, we varied the number of phenotypes
associated with the rare variants, such that not all of the tested
phenotypes will be dependent on the gene of interest. Under
models assessing ten phenotypes, we consider situations where
one, two, four, six, or eight phenotypes are actually associated
with the gene. Under models assessing six phenotypes, we
consider situations where only one, three, or five phenotypes are
associated. We control correlation among phenotypes through
consideration of the relative variance of phenotype explained by
the R causal variants. We define this relative variance for pheno-
type l as hl ¼
PR
r¼1b
2
r;l  2MAFrð1-MAFrÞ. As in Galesloot et al.,11
we define the overall correlation between phenotypes l and l’
as El;l0 ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 hl
p ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 hl0
p  Sl;l0 where Sl,l’ is (l,l’) element of the
L3 L residual phenotypic correlationmatrix. This allows the resid-
ual correlation structure among phenotypes to stay at the defined
values., 2016
For demonstration purposes, we also estimated power for
limited simulations where we considered multiple combinations
of phenotypic/genotypic similarity matrices for analyses. For
such simulations, we considered a weighted linear kernel to
form X and either the projection matrix or linear kernel to
form Y. We then implement the perturbation procedure described
above to obtain a p value accounting for the testing of the two sim-
ilarity matrices.
For all simulations and analyses reported here, unless specified
otherwise, we implement a weighting scheme based on the MAF
of each variant that weights very rare variants more heavily than
less rare variants. We selected the weighting scheme recommen-
ded by Wu et al.,31 setting wv ¼ Beta(MAFv, 1, 25)/Beta(0, 1,25).
We evaluate GAMuT using the simulated data and compare our
approach to competing strategies. For the analysis of continuous
phenotypes, we compared GAMuT to the MFLM approach of
Wang et al.25 Our implementation of MFLM used the B-spline
basis based on Pillai-Bartlett trace, selecting the default parameters
suggested by the authors for data analysis. Additionally, we
compared GAMuT to a standard rare-variant association approach
that ignored pleiotropy. Here, we consider the standard approach
to be application of the popular SKAT31 test, a powerful, kernel-
based univariate test for sequencing data. We applied SKAT to
each of the simulated phenotypes and then based inference on
the minimum SKAT p value across phenotypes analyzed. Because
we perform SKAT testing on each of our L phenotypes, we must
correct for multiple hypothesis testing. Although a permutation-
based procedure is the gold standard for multiple test correction,
it is computationally intensive and unlikely to scale to genome-
wide analysis. Instead, we perform multiple testing correction us-
ing two approaches. First, we implement a simple Bonferroni
correction of aBONFERRONI ¼ ae/L, where ae is the experimental-
wise error rate. Unfortunately, this approach can be conservative,
especially for tightly correlated phenotypes. We therefore also
consider a more liberal threshold by estimating the effective num-
ber of independent tests, Leff, where Leff is the number of principal
components necessary to explain either 98% or 90% of pheno-
typic variance in L phenotypes.48 We can then calculate a more
liberal correction of aEFFECTIVE ¼ ae/Leff. Although thresholds of
90%–98% of phenotypic variance are more liberal than 99.5%
threshold recommended by Gao et al.,48 we wanted to estimate
the upper bounds of power to detect an effect using SKAT. Correc-
tion using the permutation approach should therefore fall
somewhere between the conservative Bonferroni approach and
the liberal principal component approaches.
For the analysis of binary phenotypes, we are unaware of exist-
ing methods for testing cross-phenotype effects of rare variants.
Hence, we compared GAMuT to univariate SKAT testing only as
described in the previous paragraph.Analysis of GENOA Study
High body mass index (BMI), low high-density lipoprotein (HDL),
and high blood pressure are interrelated conditions that increase
risk of developing cardiovascular disease, stroke, kidney disease,
and type 2 diabetes. These conditions are moderately heritable.
The heritability of BMI has been estimated to be between 17%9
and 34%49 depending on methods used for the estimation. Simi-
larly, heritability of HDL is estimated at 40%–48%,49,50 and the
estimates of heritability of blood pressure range from 30%49 to
48%–67%.51 Understanding genetic factors underlying these con-
ditions is of considerable clinical importance. Several GWASs,The Ameincluding pleiotropic analyses of common variants, have been per-
formed on one or more of the conditions.52–58 These studies have
been tremendously successful in identification of common genetic
variants; however, much of the genetic underpinnings of the con-
ditions remains unexplained.59
The GENOA study32,60 seeks to identify genetic variants that in-
fluence risk for hypertension and arteriosclerotic complications of
hypertension. The GENOA resources include a cohort of African
American sibships from Jackson, Mississippi. In the initial phase
of the GENOA study, all members of sibships containingR2 indi-
viduals diagnosed with hypertension prior to age 60 were invited
to participate, including both hypertensive and normotensive
siblings. GENOA investigators collected extensive phenotypic
information on each participant, including BMI, HDL, systolic
blood pressure (SBP), and diastolic blood pressure (DBP). We
selected these continuous measures for analysis. Additionally,
GENOA investigators genotyped 1,429 subjects on the Illumina
HumanExome Beadchip. We used the HumanExome-12 support
files provided by Illumina to identify 48,712 non-singleton, rare
or less-common autosomal genetic variants (MAF < 3%; hereafter
referred to as ‘‘rare-variant’’) that fell within known genes. We
further excluded genes with fewer than 5 rare-variant sites within
the GENOA dataset, leaving 3,277 genes in our analysis. Although
GENOA collects data on sibs, GAMuT assumes study subjects are
unrelated. Therefore, we randomly selected one sibling from
each family for inclusion in our analysis.
We performed standard data cleaning, removed subjects who
did not fast for at least 10 hr prior to phenotype collection, and
removed related subjects that were either identified as relatives
via pedigree information or identified as first-degree cryptic rela-
tives identified with the program RELPAIR.61 The final sample
for analysis consisted of 539 unrelated subjects with measures of
all four phenotypes. For each of the study participants, we also ob-
tained gender, age, smoking status (ever smoked at least 100 ciga-
rettes), and use of anti-hypertension or lipid-lowering medication,
and we calculated the top ten genetic principal components using
ancestry informative markers included on the Illumina array. We
applied GAMuTusing both a projection matrix and a linear kernel
to measure pairwise phenotypic similarity. We also ran univariate
SKAT on each of the four phenotypes and adjusted for multiple
testing. For all GAMuT and SKAT tests, we used a weighted linear
kernel (selecting the weighting scheme recommended by Wu
et al.,31 described above, as we used in our simulation work) to
measure pairwise genotypic similarity. We also applied MFLM to
the GENOA dataset as a comparison. The procedures followed
were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and na-
tional) and proper informed consent was obtained.Results
Type I Error Simulations
Figure 1 shows the quantile-quantile (QQ) plots based on
application of GAMuT to null datasets consisting of
1,000 subjects assayed for ten phenotypes. We present
QQ plots both for binary and continuous phenotypes
assuming low, moderate, or high residual phenotypic cor-
relation. We provide additional QQ plots of the GAMuT
test for other combinations of phenotypes considered
and sample size in Figures S1–S3. For all models tested,rican Journal of Human Genetics 98, 525–540, March 3, 2016 529
Figure 1. GAMuT QQ Plots
The QQ plots applying GAMuT to 10,000 simulated null datasets assuming a sample size of 1,000. In each simulation, 10 phenotypes are
tested. Top row assumes binary phenotypes; bottom row assumes continuous phenotypes. Left column shows low residual phenotypic
correlation (correlation 0–0.3), middle column shows moderate residual correlation (correlation 0.3–0.5), and right column shows high
residual correlation (correlation 0.5–0.7).GAMuT properly controls for type I error, even at the
extreme tails of the test. We further investigated the type
I error of GAMuT in the presence of confounding due to
a continuous covariate (see Material and Methods section)
where we adjusted for confounding by residualizing the
phenotypes on the covariate prior to analysis. Our QQ
plots in Figure S4 show that this residualization effectively
controls for the confounding for both binary and contin-
uous phenotypes that, unadjusted, would yield inflated
results.
Table 1 shows type I error at a R 0.001 of GAMuT,
MFLM, and univariate SKAT analyses of ten phenotypes
for N ¼ 1,000 and N ¼ 2,500, and Table S1 shows similar
results when analyzing six phenotypes. As expected based
on the QQ plots in Figures 1 and S1–S3, the GAMuT
approach maintains appropriate type I error across a range
of assumptions and significance thresholds. Meanwhile,
we observed appropriate type I error rates of the MFLM
as well as SKAT tests after multiple-testing correction.
The difference in type I error between the three SKAT ap-
proaches was minor, particularly at smaller significance
thresholds. This finding is consistent with previous publi-530 The American Journal of Human Genetics 98, 525–540, March 3cations,48,62 particularly given the small number of tests
performed (either six or ten phenotypes).
Figure 2 shows GAMuT QQ plots for binary and contin-
uous phenotypes where we adjusted formultiple candidate
matrices (see Material and Methods section). The perturba-
tion procedure properly accounts for testing three combi-
nations of Y and X and properly controls for false positive
rate for a range of assumptions. By contrast, as we show in
Figures S5 (binary outcomes) and S6 (continuous out-
comes), using the minimum p value of GAMuT across
matrices tested (i.e., without multiple-testing correction)
yields inflated results, whereas the Bonferroni correction
yields deflated results.
Power Simulations
Next we compared the power of GAMuT with MFLM for
continuous traits and univariate SKATanalysis (using three
different multiple-testing corrections) for both continuous
traits and binary traits. For these power simulations, we set
sample size to 1,000. Power was estimated as the propor-
tion of p values < 2.5 3 106 (reflecting a genome-wide
correction for 20,000 genes) and was evaluated based on, 2016
Table 1. Empirical Type I Error Rates Assuming Ten Phenotypes
Sample Size
Type of
Phenotypes
Phenotypic
Correlation
a ¼ 0.05 a ¼ 0.01 a ¼ 0.001
GAMuT MFLM
SKAT
GAMuT MFLM
SKAT
GAMuT MFLM
SKAT
Bonf. PC: 98% PC: 90% Bonf. PC: 98% PC: 90% Bonf. PC: 98% PC: 90%
1,000 continuous low .0453 .0503 .0455 .0455 .0545 .0076 .0099 .0096 .0096 .0112 .0007 .0009 .0010 .0010 .0011
moderate .0504 .0481 .0423 .0423 .0503 .0085 .0095 .0097 .0097 .0115 .0013 .0007 .0012 .0012 .0013
high .0517 .0484 .0462 .0498 .0509 .0104 .0138 .0100 .0102 .0129 .0009 .0013 .0010 .0011 .0011
binary low .0488 – .0447 .0447 .0481 .0093 – .0134 .0134 .0140 .0006 – .0023 .0023 .0023
moderate .0537 – .0429 .0429 .0461 .0128 – .0105 .0105 .0115 .0013 – .0028 .0028 .0029
high .0439 – .0474 .0487 .0509 .0076 – .0082 .0088 .0096 .0003 – .0013 .0013 .0014
2,500 continuous low .0512 .0493 .0447 .0474 .0567 .0090 .0099 .0077 .0101 .0127 .0014 .0012 .0007 .0007 .0007
moderate .0538 .0506 .0402 .0416 .0547 .0107 .0114 .0080 .0090 .0113 .0012 .0008 .0010 .0010 .0012
high .0457 .0496 .0496 .0502 .0510 .0091 .0115 .0090 .0093 .0101 .0009 .0018 .0012 .0012 .0012
binary low .0491 – .0360 .0480 .0529 .0107 – .0092 .0107 .0116 .0015 – .0017 .0017 .0017
moderate .0524 – .0384 .0450 .0491 .0121 – .0098 .0102 .0113 .0018 – .0015 .0015 .0015
high .0450 – .0455 .0457 .0503 .0081 – .0110 .0117 .0120 .001 – .0012 .0014 .0014
Empirical size for GAMuT, MFLM, and SKAT analyses at significance thresholds of 0.05, 0.01, and 0.001. Empirical size calculated from 10,000 null simulations. Simulations assume analysis of 10 phenotypes. Sample size was
set at either 1,000 or 2,500. Phenotypes were either continuous or dichotomous. Phenotypic correlation was low (correlation < 0.3), moderate (correlation 0.3–0.5), or high (correlation 0.5–0.7).
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Figure 2. QQ Plots for GAMuT Assuming Multiple Matrices Tested
The QQ plots applying GAMuT to 10,000 simulated null datasets assuming a sample size of 1,000. p values using three candidate
matrices combinations were obtained for each simulation. We then implement a perturbation procedure to obtain a p value accounting
for testing the three combinations of similarity matrices. In each simulation, ten phenotypes are tested. Top row assumes binary
phenotypes; bottom row assumes continuous phenotypes. Left column shows low residual phenotypic correlation (correlation
0–0.3), middle column shows moderate residual correlation (correlation 0.3–0.5), and right column shows high residual correlation
(correlation 0.5–0.7).500 replicates of the data per model. Figure 3 shows the
power results when we analyze continuous phenotypes.
We plot power as a function of the number of phenotypes
that are truly associated with the causal variants. The figure
clearly shows that GAMuT outperforms both MFLM and
the standard univariate SKAT approach for all models
considered. The difference in power between the three
SKAT approaches was negligible; therefore, we show only
90% cutoff to determine the effective number of indepen-
dent tests, because it is the most anti-conservative correc-
tion method. As expected, GAMuT performs particularly
well against SKAT and MFLM as the ratio of associated to
unassociated phenotypes increases (i.e., as the gene is
increasingly pleiotropic). In addition, under models of no
pleiotropy where rare causal variants were associated
with only one of the phenotypes under consideration,
we observed the power of GAMuT to be approximately
equal or better than SKAT.
MFLM performs poorly in all of our assumptions. We
therefore simulated data that mimics the assumptions pre-532 The American Journal of Human Genetics 98, 525–540, March 3sented in the top row of Wang et al.’s Figure 4.25 The
differing assumptions are detailed in Figure S7; in brief,
the differences in our assumptions compared with the
Wang et al. manuscript are that the latter work assumes
smaller number of phenotypes, smaller genes, larger effect
sizes, a more lenient significance threshold, and a larger
percentage of causal variants. When we implement the
simulation strategy of Wang et al., we observe increases
in power for MLFM versus SKAT that are similar to those
in their paper. GAMuT performance is approximately
equivalent to MLFM under the simulation assumptions
of Wang et al.
Figure 4 shows similar results when binary phenotypes
are modeled. Because MFLM is valid only for continuous
outcomes, we compare GAMuT only to univariate SKAT
for binary outcomes. We observed similar improvements
of power for GAMuT compared to SKAT in our binary sim-
ulations as we did for our continuous simulations. Under
pleiotropic models, the improvement in power of GAMuT
over SKAT grows more noticeable as the number of, 2016
Figure 3. Power to Detect Cross-Phenotype Effects: Continuous Phenotypes
Power for GAMuT (red), univariate SKAT using a 90% cutoff to determine effective number of independent tests (blue), and MFLM
(green) is plotted as a function of number of continuous phenotypes associated with the gene of interest. Top row assumes six contin-
uous phenotypes are tested in each simulation, and bottom row assumes ten continuous phenotypes are tested. Left column shows low
residual phenotypic correlation (correlation 0–0.3), middle column shows moderate residual correlation (correlation 0.3–0.5), and right
column shows high residual correlation (correlation 0.5–0.7).phenotypes associated with the gene increases. At the
same time, even under power models where there is no
pleiotropy (only one phenotype associated with the rare
variants), our results indicate GAMuT is at least as powerful
compared with the univariate SKAT approaches under
models assuming low correlation, and in fact is more
powerful than the univariate approach under moderate
and high correlation structure.
We also implemented the perturbation approach to
model phenotypic similarity using both the projectionma-
trix and the linear kernel. For both cases, we used the
weighted linear kernel to model genotypic similarity. In
Figure 5 we compare power of GAMuTusing the projection
matrix against power when two candidate matrices are
considered (projection and linear kernel), implementing
the perturbation procedure to account for testing two com-
binations of Y. Power in Figure 5 is defined as the propor-
tion of p values less than 1.5 3 105, to reflect the study-
wide significance threshold we will use for the GENOA
data. We also show power using the linear kernel to model
phenotypic similarity. Although the linear kernel was not
as powerful as the projection matrix on our simulated
data, simulations indicate that the perturbation procedure
retains much of the power of the optimal kernel approach.The AmeApplication to GENOA Dataset
We use the GENOA dataset to test for associations between
BMI, HDL, SBP, DBP, and rare variants in 3,277 genes. Prior
to analysis by GAMuT, we controlled for gender, age, smok-
ing status, use of anti-hypertension medication, use of
lipid-lowering medication, and ancestry on the 539 unre-
lated subjects. After adjusting for covariates, correlation
of the four phenotypes was low to moderate with the
largest pairwise correlation (0.67, Pearson’s product-
moment correlation p value < 2.2 3 1016) between
SBP and DBP (see Table 2). We applied GAMuT using
both a projection matrix and a linear kernel to measure
pairwise phenotypic similarity. For comparison, we ran
MFLM as well as univariate SKAT on each of the four
phenotypes and adjusted for multiple testing. For all
GAMuT and SKAT tests, we used a weighted linear kernel
tomeasure pairwise genotypic similarity.We set a stringent
study-wise significance threshold of 1.5 3 105, which
corresponds to a Bonferroni correction based on the
number of genes tested (3,277): aBONFERRONI ¼ 0.05/
3,277. We considered p values less than p < 1 3 103 as
suggestive.
Figure 6 provides genome-wide results using GAMuTand
univariate SKAT analyses with top findings highlightedrican Journal of Human Genetics 98, 525–540, March 3, 2016 533
Figure 4. Power to Detect Cross-Phenotype Effects: Binary Phenotypes
Power for GAMuT (red) and univariate SKATusing a 90% cutoff to determine effective number of independent tests (blue) is plotted as a
function of number of binary phenotypes associated with the gene of interest. Top row assumes six binary phenotypes are tested in each
simulation, and bottom row assumes ten binary phenotypes are tested. Left column shows low residual phenotypic correlation (corre-
lation 0–0.3), middle column shows moderate residual correlation (correlation 0.3–0.5), and right column shows high residual correla-
tion (correlation 0.5–0.7).in Table 3. None of the methods identified any genes asso-
ciated at the study-wide significance threshold. Using the
linear kernel, GAMuT identified five genes of suggestive
significance. Of note, SELP, which was identified as sug-
gestive significance by GAMuT (p ¼ 1.9 3 104), has
previously been associated with traits related to the four
GENOA phenotypes. Haplotypes or common polymor-
phisms in SELP have been associated with myocardial
infarction63,64 and thromboembolic stroke.65 Levels of
P-selectin, the protein encoded by SELP, is increased in
hypercholesterolemic individuals66 and individuals with
unstable angina.67 P-selectin levels were significantly asso-
ciated with carotid artery stiffness and wall thickness
among Japanese individuals with type II diabetes, hyper-
tension, or hyperlipidemia.68 The same study found that
percentage of P-selectin-positive platelets was positively
associated with BMI, SBP, and DBP and inversely associated
with HDL.
The projection matrix form of GAMuT identified four
genes of suggestive significance. p values from the two
forms of GAMuTwere strongly correlated (Pearson correla-
tion ¼ 0.90). After accounting for confounders, GAMuT
did not demonstrate any systematic inflation across the
genome (see QQ plots in Figure 6).534 The American Journal of Human Genetics 98, 525–540, March 3In order to correct for using two phenotypic similarity
matrices for GAMuT, we performed the perturbation
approach described in the Material and Methods on the
eight genes with p values of less 13 103 for either GAMuT
or SKAT. The p values obtained through combined pertur-
bation method are also shown in Table 3. Of the eight
genes identified as suggestive by either or both of the
GAMuTapproaches, five remained suggestive after correct-
ing for use of two GAMuT similarity matrices (including
SELP).
We investigated whether our top genetic associations for
the modeled phenotypes (SBP/DBP/HDL/BMI) in Table 3
were possibly spurious due to the fact that the phenotypes
analyzed are secondary phenotypes collected in a study as-
certained on a correlated primary phenotype (hyperten-
sion). To verify that a confounding association between
rare-variant genotypes at our top genes and hypertension
was not driving our results, we performed univariate
SKAT testing of our top genes in Table 3 on the primary hy-
pertension variable. We observed none of our top genes to
be significantly associated with hypertension.
The SKAT p values using the three multiple testing
correction methods were identical across all genes
tested. SKAT did not identify any genes at genome-wide, 2016
Figure 5. Power to Detect Pleiotropic Effect using Multiple Sim-
ilarity Matrices
Power for GAMuT assuming a projection matrix (red), GAMuT
assuming a linear kernel (yellow), GAMuT assuming testing of
both projection matrix and linear kernel (orange), univariate
SKAT using a 90% cutoff to determine effective number of inde-
pendent tests (blue), and MFLM (green). In each simulation, ten
continuous phenotypes with moderate residual correlation (corre-
lation 0.3–0.5) are tested.
Table 2. Correlation of GENOA Phenotypes
BMI HDL SBP DBP
BMI 1 -0.17* 0.09* 0.02
HDL – 1 0.01 0.03
SBP – – 1 0.67*
DBP – – – 1
Correlation among the four GENOA phenotypes: bodymass index (BMI), high-
density lipoprotein (HDL), systolic blood pressure (SBP), and diastolic blood
pressure (DBP). Asterisk indicates correlations are nominally significant (Pear-
son’s product-moment correlation p value < 0.05).significance. It identified four genes at the suggestive sig-
nificance threshold, all of which were identified by one
or both of the GAMuT tests. When we applied MFLM to
the GENOA data, we observed sizeable inflation of the
p values. The p value inflation was not resolved by in-
verse-normal transforming the phenotypes, as performed
in Wang et al.25 See Figure S8 for QQ plots of the untrans-
formed and transformed analyses.
Running the GAMuT analyses on a single-threaded R
script on an Intel i7-2720QM CPU took 22.3 min using
either the linear kernel or the projection matrix to model
phenotypic similarity. Implementing the perturbation
approach (1 3 106 replicates per gene) required approxi-
mately 44.5 min of computing time per gene analyzed.Discussion
Some patterns in the genetic basis of complex traits have
emerged in prior studies. First, common variants of rela-
tively small individual effect located throughout the
genome collectively explain a large fraction of the total ge-
netic variance.9,69–78 Second, for some disorders such as
autism,79,80 more than a thousand genes appear capable
of harboring exceedingly rare, large-effect mutations.
Although it is still unclear whether these two patterns are
ubiquitous, they are central predictions of the infinitesimalThe Amemodel of allele effects. Moreover, we know from detailed
theoretical analysis3 that if the infinitesimal model is
true for most phenotypes, then most rare large-effect mu-
tations should be highly pleiotropic.
We have presented GAMuT, a framework for cross-
phenotype analysis of rare variants using a nonparametric
distance-covariance approach.26,27,30 This approach can
accommodate both binary and continuous phenotypes
and can adjust for covariates. The GAMuT test derives an-
alytic p values based on Davies’ exact method, thereby
improving computational efficiency and permitting appli-
cation on a genome-wide scale. Like the popular SKAT
framework for univariate rare variant analysis, our
approach allows for inclusion of prior information, such
as biological plausibility of the variants under study, and
further remains powerful when a gene harbors a mixture
of rare causal variants that act in different directions on
phenotype. Our approach demonstrates greater power
than SKAT and MFLM when pleiotropy exists. Further,
simulations indicate that even if only one phenotype is
associated with the gene of interest (i.e., no pleiotropy is
occurring), GAMuT is at least as powerful as univariate
SKAT analyses after multiple-testing adjustment. These re-
sults hold for both continuous and binary outcomes.
We provide R software implementing GAMuT on our
website (see Web Resources), which can be run through
software packages like PLINK, PLINK-SEQ, or EPACTS if
desired. GAMuT analysis of simulated datasets comprised
of 1,000 subjects and 10 phenotypes takes 0.52 s per
gene for either continuous or binary phenotypes using a
R script running single-threaded on an a 1.7 GHz Intel
Core i7 CPU processor. Increasing the number of pheno-
types or rare variants tested does not substantially increase
GAMuT’s run-time. However, increasing sample size does
increase run time. For sample sizes of N ¼ 2,500, 5,000,
10,000, 20,000, and 30,000 subjects, we found that
GAMuT takes approximately 4.1 s, 13.2 s, 68.6 s, 580 s,
and 3,600 s per gene, respectively, for either continuous
or binary phenotypes. Based on these estimates, we feel
genome-wide analysis using GAMuT is feasible even with
enormous sample sizes with the aid of parallel computing.
GAMuT’s perturbation approach to adjust for multiple
combinations of phenotype/genotype similarity matrices
when testing a gene is computationally far more efficientrican Journal of Human Genetics 98, 525–540, March 3, 2016 535
Figure 6. Results of GENOA Analyses
Left column shows Manhattan and QQ plots for GAMuT using a projection matrix for phenotypes. Middle column shows Manhattan
and QQ plots for GAMuT using a linear kernel for phenotypes. Right column shows Manhattan and QQ plots for SKAT, using a 90%
cutoff to determine the effective number of independent tests. Horizontal blue line indicates suggestive significance threshold. Horizon-
tal red line indicates study-wide significance.than permutations but still remains intensive. For a sample
size of 10K, the total computation time required to run
K ¼ 106 perturbations for a single gene is ~5–6 hr for
M ¼ 2 combinations and ~10–12 hr for M ¼ 4 combina-
tions. Computation timescales linearly with number of
perturbations performed and number of combinations as-
sessed. Sample size has only a minor effect on perturbation
run time; for example, increasing sample size by a factor of
10 increases computation time only by a factor of approx-
imately 2. Although perturbations are computationally
demanding, we note that we can circumvent this compu-
tational issue in a couple of ways. First, we can elect to
apply the perturbation approach to just the small set of
genes with a minimum unadjusted p value (across the M
combinations considered) smaller than the unadjusted
genome-wide significance threshold; genes that fail to536 The American Journal of Human Genetics 98, 525–540, March 3meet this criteria will be of little or no interest for follow
up. This strategy is a variation of the strategy we applied
in our GENOA analyses. Alternatively, if one wanted to
apply the perturbation procedure to each of 20,000 genes,
then one could consider an adaptive perturbation strategy
similar in logic to the adaptive permutation procedure in
PLINK81 to adjust for multiple testing in GWASs. We will
explore this idea in future work.
We applied GAMuT to exome-chip data from the
GENOA study to identify genes harboring rare variants
with cross-phenotype effects on four phenotypes: BMI,
HDL levels, SBP, and DBP. Using the linear kernel to model
phenotypic similarity and the weighted linear kernel to
model genotypic similarity, we detected eight genes that
were suggestively associated with our phenotypes. Of
note, common variants and gene product levels of one, 2016
Table 3. Top GENOA Results
Gene Symbol MIM Number Chromosome
Number Rare
Variants
GAMuT
SKAT: 90% PCProjection Matrix Linear Kernel
Combined
(Perturbation)
SELP 173610 1 8 4.8 3 103 1.9 3 104 2.8 3 104 4.9 3 104
DISP1 607501 1 8 1.0 3 104 8.1 3 103 1.4 3 104 7.3 3 103
ARHGEF10 608136 8 14 2.8 3 102 7.9 3 104 1.0 3 103 6.6 3 104
COL17A1 113811 10 11 6.3 3 104 1.1 3 103 9.2 3 104 9.0 3 103
STRA6 610745 15 7 1.1 3 103 9.9 3 104 1.5 3 103 3.4 3 103
ZNF222 NA 19 5 8.8 3 104 3.6 3 103 1.4 3 103 4.5 3 104
COL9A3 120270 20 5 5.6 3 105 2.2 3 105 2.3 3 105 6.7 3 104
FAM83F NA 22 5 3.8 3 103 4.4 3 104 6.6 3 104 9.3 3 103
We identified eight genes in the GENOA dataset with p values of at least suggestive significance (p < 1 3 103) using either GAMuT or SKAT, using a 90% cutoff
to determine the effective number of independent tests. For the eight genes we provide gene name, chromosomal location of gene, number of rare variants
(MAF < 3%) found in each gene in the GENOA dataset, and p values for the four approaches.such gene, Selectin P (SELP [MIM: 173610]), have previ-
ously been associated with BMI, SBP, DBP, and HDL.66,68
GAMuT’s KDC framework is amenable to several prom-
ising extensions that we will explore in future work.
Because GAMuT is an omnibus test, an association of the
gene with just one of the tested phenotypes (i.e., no pleiot-
ropy) could result in a significant finding. Although the
result is valid, researchers will often wish to identify which
underlying phenotype(s) of those modeled are directly
associated with the gene of interest. Additionally, if we
identify a cross-phenotype association, a follow-up anal-
ysis could be to assess whether the cross-phenotype effect
is due to biological pleiotropy (a causal locus directly
affecting more than one trait) or mediation pleiotropy
(a causal locus affecting only one trait, which in turn
affects another trait). Existing mediation analyses are not
intended to handle high-dimensional traits; we propose
the creation of KDC procedures to identify whether an
observed cross-phenotype association is mediated by a
different set of phenotypes. Additionally, we could also
perform post hoc GAMuT of different subgroupings of
the phenotypes to identify the true phenotypes associated
with the gene and adjust for multiple testing using pertur-
bations. We will pursue these ideas in future work.
GAMuT currently assumes unrelated subjects; however,
it should be reasonably straightforward to extend GAMuT
to allow for case-parent trio studies. The work by Jiang
et al.82 provides a framework for transforming genotypic
data for trios into data that is amenable to a kernel-based
framework. Specifically, the Jiang method uses the quanti-
tative transmission disequilibrium test introduced by
Abecasis et al.83 to decompose observed genotypes into
between-family and within-family components, and then
integrates within-family genetic components into a
kernel-machine regression framework. Although the Jiang
method uses a KMR approach and is therefore appropriate
only for univariate phenotype analyses, an analogous
approach, using GAMuT, should allow for high-dimen-The Amesional phenotype data. Finally, one might be interested
in combining cross-phenotype association results from
multiple studies through a meta-analysis. GAMuT is de-
signed to test for rare variant cross-phenotype associations
in a single dataset. However, themeta-analysis approach in
Lee et al.,84 which is designed to combine results of multi-
ple KMR-based studies, should be readily extendible to
KDC results, such as those obtained via GAMuT.
That pleiotropy might be ubiquitous should come as no
surprise. The central organismal level result of pleiotropy
will be the frequent occurrence of comorbid diagnoses.
Neuropsychiatric disorders, for instance, are particularly
laden with comorbid diagnoses. The National Institute of
Mental Health (NIMH) estimates that as many as 45% of
individuals diagnosed with a mental disorder meet criteria
for two or more disorders.85 Likewise, nearly 75% of adults
with diabetes also have hypertension,86 and individuals
with rheumatoid arthritis are about twice as likely to
suffer from myocardial infarction as individuals without
arthritis.87 Although some of these overlapping pheno-
types are ultimately due to environmental risk factors,
other comorbidities are almost certainly explained by com-
mon genetic pathways. Ignoring comorbidity, or worse,
setting inclusion criteria that exclude individuals suffering
a comorbid diagnosis, will limit biological understanding
of complex traits and might limit our ability to detect
missing heritability.Supplemental Data
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